Research programme: CXCR3 antagonists - Pfizer

Drug Profile

Research programme: CXCR3 antagonists - Pfizer

Latest Information Update: 20 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action CXCR3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Myositis

Most Recent Events

  • 03 Nov 2017 Preclinical trials in Myositis in USA (Parenteral)
  • 03 Nov 2017 Pharmacodynamics data from preclinical studies in Myositis presented at the 81st American College of Rheumatology and the 52nd Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top